Author

T. E. Moustafa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:imaging· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

T. A. Zangle· 2 shared A. Butterfield· 1 shared A. Lex· 1 shared B. E. Welm· 1 shared B. K. Lohman· 1 shared B. T. Spike· 1 shared C. Stubben· 1 shared D. Grossman· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

T. A. Zangle

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer

E. R. Polanco, T. E. Moustafa, A. Butterfield, S. D. Scherer, E. Cortes-Sanchez, T. Bodily, B. T. Spike, B. E. Welm, P. S. Bernard, T. A. Zangle

This study uses multiparametric quantitative phase imaging to assess drug response in breast cancer cells, revealing single-cell heterogeneity and resistance dynamics.

bioRxiv · Nov 26, 2021Bioengineering

Bidirectional interconversion between mutually exclusive tumorigenic and drug-tolerant melanoma cell phenotypes

Y. Zhang, R. L. Belote, M. A. Urquijo, M. M. Hansen, M. Hejna, T. E. Moustafa, T. Liu, D. Lange, F. Vand-Rajabpour, M. Chang, B. K. Lohman, C. Stubben, X. Zhang, L. S. Weinberger, M. W. VanBrocklin, , R. L. Judson-Torres

This study identifies bidirectional interconversion between tumorigenic and drug-tolerant melanoma cell states through BRN2 expression, revealing distinct molecular programs and therapeutic implications.

bioRxiv · Aug 26, 2020 · PreprintCancer Biology